Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa - PubMed (original) (raw)

Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa

Mikko Kuoppamäki et al. Mov Disord. 2002 Nov.

Abstract

A wide range of motor fluctuations develop in Parkinson's disease (PD) patients after prolonged levodopa (L-dopa) treatment, but few experimental models exist in which these can be investigated. We report on motor fluctuations occurring in MPTP-treated common marmosets (Callithrix jacchus) treated repeatedly with L-dopa. All animals showed an improvement in motor function in response to L-dopa, and rapidly developed peak-dose dyskinesia. During the period of L-dopa action, brief periods of immobility were occasionally observed. After acute L-dopa challenge, animals exhibited a worsening of motor function before improvement, and after the beneficial response to L-dopa declined, motor performance showed rebound worsening to below-baseline values. Before L-dopa challenge and during wearing-off and rebound worsening, leg dystonias were observed. Although these findings cannot necessarily be generalized to all MPTP-treated nonhuman primates, they demonstrate that MPTP-treated marmosets show a range of different motor fluctuations analogous to those seen in PD patients chronically treated with L-dopa. Therefore, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates can provide a model in which the pathophysiology of treatment complications can be investigated.

Copyright 2002 Movement Disorder Society

PubMed Disclaimer

Similar articles

• The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
  Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Hansard MJ, et al. Mov Disord. 2004 Jan;19(1):15-21. doi: 10.1002/mds.10596. Mov Disord. 2004. PMID: 14743355
• Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
  Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Pearce RK, et al. Mov Disord. 1995 Nov;10(6):731-40. doi: 10.1002/mds.870100606. Mov Disord. 1995. PMID: 8749992
• De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
  Pearce RK, Banerji T, Jenner P, Marsden CD. Pearce RK, et al. Mov Disord. 1998 Mar;13(2):234-41. doi: 10.1002/mds.870130207. Mov Disord. 1998. PMID: 9539335
• The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
  Jenner P. Jenner P. Neurology. 2003 Sep 23;61(6 Suppl 3):S4-11. doi: 10.1212/wnl.61.6_suppl_3.s4. Neurology. 2003. PMID: 14504374 Review.
• Investigating levodopa-induced dyskinesias in the parkinsonian primate.
  Langston JW, Quik M, Petzinger G, Jakowec M, Di Monte DA. Langston JW, et al. Ann Neurol. 2000 Apr;47(4 Suppl 1):S79-89. Ann Neurol. 2000. PMID: 10762135 Review.

Cited by

• Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
  Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG. Gunzler SA, et al. Arch Neurol. 2008 Feb;65(2):193-8. doi: 10.1001/archneurol.2007.58. Arch Neurol. 2008. PMID: 18268187 Free PMC article. Clinical Trial.
• Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
  Lane E, Dunnett S. Lane E, et al. Psychopharmacology (Berl). 2008 Aug;199(3):303-12. doi: 10.1007/s00213-007-0931-8. Epub 2007 Sep 25. Psychopharmacology (Berl). 2008. PMID: 17899020 Review.
• Patterns of Beginning of Dose Motor Deterioration: A New Look at an Old Phenomenon.
  Morales-Briceño H, Tsui D, Ong TL, Fung VSC, Babu S, Mahant N. Morales-Briceño H, et al. Mov Disord Clin Pract. 2022 Jun 8;9(5):712-716. doi: 10.1002/mdc3.13470. eCollection 2022 Jul. Mov Disord Clin Pract. 2022. PMID: 35844275 Free PMC article. No abstract available.
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
  Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley